Latest news

Week in Brussels: China, Dutch Mercosur vote, Australia, Myanmar, Bangladesh
A week in Brussels Australia & New Zealand GSP, GSP Plus, EBA Intellectual property Latest news

Week in Brussels: China, Dutch Mercosur vote, Australia, Myanmar, Bangladesh

This week has been dominated by news and gossip surrounding the nomintion of a successor for the WTO’s outgoing director general. Today, Nigeria announced it was planning to nominate former finance minister and World Bank official Ngozi Okonjo-Iweala – a high profile nomination to say the least. The nomination period …

Cambodia EBA suspension in shadow of COVID-19 and November ASEM summit
Cambodia GSP, GSP Plus, EBA Latest news

Cambodia EBA suspension in shadow of COVID-19 and November ASEM summit

A few weeks before the Big Lockdown, the European Union announced it was suspending trade preferences enjoyed by Cambodia under Brussels’ flagship duty-free-quota-free trade regime for the world’s poorest countries. Despite the severe economic and supply chain damage wrought by the pandemic, the EU still appears to plan on pressing …

Week in Brussels: WTO, human rights due diligence, Korea thermal paper, document transparency
Korea Latest news Social & human rights Stats & data Trade defence

Week in Brussels: WTO, human rights due diligence, Korea thermal paper, document transparency

The trade week in the EU was significant, with new orientiations for policy spelt out as part of the bloc’s post-corona recovery plan. WTO: But the week in not entirely over as members of the WTO General Council meet today and next Tuesday online to confer about the next steps …

Plenary session - Votes
European Parliament Intellectual property Latest news Regulations Steel

INTA committee: pharma IP, enforcement regulation, steel, chief enforcement officer

Today the international trade committee met for a somewhat longer session than the one held at the end of April at the height of Europe’s lockdown. Here some highlights of what’s been said. Pharma intellectual property The pharmaceutical intellectual property space is one to watch very closely post COVID-19. It …